Pharmaceutical

China’s NMPA authorises Santen’s glaucoma treatment application

China’s NMPA has granted approval for the marketing authorisation application of Santen Pharmaceutical's Tapcom.

Apr 8, 2025 - 06:00
China’s NMPA authorises Santen’s glaucoma treatment application
China’s NMPA has granted approval for the marketing authorisation application of Santen Pharmaceutical's Tapcom.
Read the original article

Tags:

Previous Article

Rhythm seeks market expansion for Imcivree following Phase III victory

Next Article

Obesity drugs won’t be covered by Medicare under 2026 CMS policy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves AstraZeneca, Ionis treatment for rare nerve disease

FDA approves AstraZeneca, Ionis treatment for rare nerv...

Dec 21, 2023

Lenmeldy becomes world’s most expensive drug

Lenmeldy becomes world’s most expensive drug

Apr 3, 2024

STAT+: ViiV Healthcare and Doctors Without Borders tussle over contract terms for an HIV drug

STAT+: ViiV Healthcare and Doctors Without Borders tuss...

Aug 17, 2023